Product Review: Lynparza (Olaparib®)

In this review:

Olaparib (Lynparza®) is a poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitor indicated for  the maintenance treatment of patients with high-grade serous ovarian cancer (HGSOC), a disease with high recurrence rates and poor survival outcomes. This review focusses on the key characteristics of olaparib and provides a summary of the clinical trial data from the SOLO-1 and SOLO-2 studies, including quality of life analyses.

Please login below to download this issue (PDF)